226 related articles for article (PubMed ID: 24715445)
1. PET tracers in musculoskeletal disease beyond FDG.
Wieder HA; Pomykala KL; Benz MR; Buck AK; Herrmann K
Semin Musculoskelet Radiol; 2014 Apr; 18(2):123-32. PubMed ID: 24715445
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of positron emission tomographic tracers for imaging of papillomavirus-induced tumors in rabbits.
Probst S; Wiehr S; Mantlik F; Schmidt H; Kolb A; Münch P; Delcuratolo M; Stubenrauch F; Pichler BJ; Iftner T
Mol Imaging; 2014; 13():. PubMed ID: 24622808
[TBL] [Abstract][Full Text] [Related]
3. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cell proliferation, protein, and glucose metabolism in musculoskeletal tumors in a PET study.
Tian M; Zhang H; Endo K
J Biomed Biotechnol; 2011; 2011():807929. PubMed ID: 21738405
[TBL] [Abstract][Full Text] [Related]
5. [Tracers in oncology - preclinical and clinical evaluation].
Krause BJ; Schwarzenböck S; Schwaiger M
Nuklearmedizin; 2010; 49 Suppl 1():S41-5. PubMed ID: 21152689
[TBL] [Abstract][Full Text] [Related]
6. Advances in positron emission tomographic imaging of lung cancer.
Chen DL; Dehdashti F
Proc Am Thorac Soc; 2005; 2(6):541-4, 512. PubMed ID: 16352762
[TBL] [Abstract][Full Text] [Related]
7. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
Buck AK; Herrmann K; Büschenfelde CM; Juweid ME; Bischoff M; Glatting G; Weirich G; Möller P; Wester HJ; Scheidhauer K; Dechow T; Peschel C; Schwaiger M; Reske SN
Clin Cancer Res; 2008 May; 14(10):2970-7. PubMed ID: 18445694
[TBL] [Abstract][Full Text] [Related]
8. Comparison of [18F]-tracers in various experimental tumor models by PET imaging and identification of an early response biomarker for the novel microtubule stabilizer patupilone.
Ebenhan T; Honer M; Ametamey SM; Schubiger PA; Becquet M; Ferretti S; Cannet C; Rausch M; McSheehy PM
Mol Imaging Biol; 2009; 11(5):308-21. PubMed ID: 19462209
[TBL] [Abstract][Full Text] [Related]
9. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review.
Treglia G; Giovannini E; Di Franco D; Calcagni ML; Rufini V; Picchio M; Giordano A
Ann Nucl Med; 2012 Jul; 26(6):451-61. PubMed ID: 22566040
[TBL] [Abstract][Full Text] [Related]
10. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors.
Peterson JJ
Semin Musculoskelet Radiol; 2007 Sep; 11(3):246-60. PubMed ID: 18260035
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in urologic oncology: positron emission tomography molecular imaging.
Bouchelouche K; Oehr P
Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
[TBL] [Abstract][Full Text] [Related]
12. Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging.
Kumar R; Dhanpathi H; Basu S; Rubello D; Fanti S; Alavi A
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):50-65. PubMed ID: 18235421
[TBL] [Abstract][Full Text] [Related]
13. Non-[18F]FDG PET in clinical oncology.
Groves AM; Win T; Haim SB; Ell PJ
Lancet Oncol; 2007 Sep; 8(9):822-30. PubMed ID: 17765191
[TBL] [Abstract][Full Text] [Related]
14. Non FDG PET.
Nanni C; Fantini L; Nicolini S; Fanti S
Clin Radiol; 2010 Jul; 65(7):536-48. PubMed ID: 20541653
[TBL] [Abstract][Full Text] [Related]
15. Non-FDG PET in the practice of oncology.
Caroli P; Nanni C; Rubello D; Alavi A; Fanti S
Indian J Cancer; 2010; 47(2):120-5. PubMed ID: 20448372
[TBL] [Abstract][Full Text] [Related]
16. Proliferation imaging with ¹⁸F-fluorothymidine PET/computed tomography: physiologic uptake, variants, and pitfalls.
Herrmann K; Buck AK
PET Clin; 2014 Jul; 9(3):331-8. PubMed ID: 25030396
[TBL] [Abstract][Full Text] [Related]
17. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast.
Langsteger W; Heinisch M; Fogelman I
Semin Nucl Med; 2006 Jan; 36(1):73-92. PubMed ID: 16356797
[TBL] [Abstract][Full Text] [Related]
18. [Is 3'-deoxy-3'- [18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?].
Couturier O; Leost F; Campone M; Carlier T; Chatal JF; Hustinx R
Bull Cancer; 2005 Sep; 92(9):789-98. PubMed ID: 16203269
[TBL] [Abstract][Full Text] [Related]
19. Molecular imaging (PET) of brain tumors.
Basu S; Alavi A
Neuroimaging Clin N Am; 2009 Nov; 19(4):625-46. PubMed ID: 19959009
[TBL] [Abstract][Full Text] [Related]
20. Utilization of positron emission tomography in the management of patients with sarcoma.
Benz MR; Tchekmedyian N; Eilber FC; Federman N; Czernin J; Tap WD
Curr Opin Oncol; 2009 Jul; 21(4):345-51. PubMed ID: 19412096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
